Companion Diagnostics - Global Market Outlook (2015-2022)

Companion Diagnostics - Global Market Outlook (2015-2022)

  • Published: March 2016
  • ID: SMRC15620

According to Stratistics MRC, the Global Companion Diagnostics Market is accounted for $2.62 billion in 2015 and is estimated to reach $9.27 billion by 2022 growing at a CAGR of 19.78% during the forecast period. At present, increasing demand for personalized medicine is mostly contributing to the global companion diagnostics market growth. On the other hand, cost allied with developing drugs could hamper the market. Developing companion diagnostics for several central nervous system conditions and hereditary conditions provide ample of opportunities for players in the market.

In terms of revenue, Breast cancer commanded the global companion diagnostics market. However, lung cancer is expected to lead the market in future growing at a significant CAGR owing to the discovery of biomarkers that are precise to lung cancer, and the discovery of myriad pertinent companion diagnostics. Molecular diagnostics is highest revenue generating segment and also expected to grow at a faster rate, mainly owing to the use of techniques such as real time PCR, In Situ Hybridization and next generation sequencing.

North America represented the largest market for companion diagnostics, followed by the Europe. The Asia Pacific and Rest of the World regions are anticipated to witness substantial demand for companion diagnostics in the future. In these regions, enhancing healthcare infrastructure, rising disposable incomes, and unexploited potential for companion diagnostics are cited as the major reasons for the market growth.

Some of the key players in the market include are Roche Diagnostics, Quest Diagnostics Inc.Qiagen N.V., Labcorp, Genomic Health Inc., Dako (Agilent Technologies), Celera, Biomerieux Sa, Abbott Laboratories, Thermo Fisher Scientific, Inc., Danaher Corporation, GE Healthcare, Biogenex Laboratories, Siemens and AstraZeneca.

Technologies Covered:
• Molecular diagnostics 
• In Situ Hybridization (ISH) 
o CISH
o FISH
• Polymerase Chain Reaction (PCR)
• Next generation sequencing
• Other Technologies
• Immunohistochemistry  

Applications Covered: 
• Colorectal Cancer  
• Gastric Cancer  
• Lung Cancer  
• Breast Cancer 
• Melanoma  
• Other Applications 

Indications Covered:
• Cardiovascular conditions 
• Inflammation  
• Virology 
• Oncology 
• Other Indications 

End User’s Covered:
• Pharmaceutical Companies  
• Reference Lab 
• Physicians 
• Hospitals  
• Academic Medical Centers 

Regions Covered:
• North America
o US
o Canada
o Mexico
• Europe
o Germany
o France
o Italy
o UK 
o Spain     
o Rest of Europe 
• Asia Pacific
o Japan       
o China       
o India       
o Australia       
o New Zealand      
o Rest of Asia Pacific      
• Rest of the World
o Middle East
o Brazil
o Argentina
o South Africa
o Egypt

What our report offers:
- Market share assessments for the regional and country level segments
- Market share analysis of the top industry players
- Strategic recommendations for the new entrants
- Market forecasts for a minimum of 7 years of all the mentioned segments, sub segments and the regional markets
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements

1 Executive Summary 
   
2 Preface  

 2.1 Abstract 
 2.2 Stake Holders
 2.3 Research Scope
 2.4 Research Methodology
  2.4.1 Data Mining
  2.4.2 Data Analysis
  2.4.3 Data Validation
  2.4.4 Research Approach
 2.5 Research Sources
  2.5.1 Primary Research Sources
  2.5.2 Secondary Research Sources
  2.5.3 Assumptions
   
3 Market Trend Analysis
 3.1 Introduction
 3.2 Drivers 
 3.3 Restraints
 3.4 Opportunities
 3.5 Threats 
 3.6 Technology Analysis
 3.7 Application Analysis
 3.8 End User Analysis
 3.9 Emerging markets
   
4 Porters Five Force Analysis
 4.1 Bargaining power of suppliers
 4.2 Bargaining power of buyers
 4.3 Threat of substitutes
 4.4 Threat of new entrants
 4.5 Competitive rivalry
   
5 Global Companion Diagnostics Market, By Technology
 5.1 Introduction
 5.2 Molecular diagnostics
  5.2.1 In Situ Hybridization (ISH)
   5.2.1.1 CISH
   5.2.1.1.2 FISH
  5.2.2 Polymerase Chain Reaction (PCR)
  5.2.3 Next generation sequencing
  5.2.4 Other Technologies
 5.3 Immunohistochemistry
   
6 Global Companion Diagnostics Market, By Application
 6.1 Introduction
 6.2 Colorectal Cancer 
 6.3 Gastric Cancer 
 6.4 Lung Cancer 
 6.5 Breast Cancer
 6.6 Melanoma 
 6.7 Other Applications
   
7 Global Companion Diagnostics  Market, By Indication
 7.1 Introduction
 7.2 Cardiovascular conditions
 7.3 Inflammation 
 7.4 Virology 
 7.5 Oncology 
 7.6 Other Indications
   
8 Global Companion Diagnostics  Market, By End User
 8.1 Introduction
 8.2 Pharmaceutical Companies
 8.3 Reference Lab
 8.4 Physicians
 8.5 Hospitals 
 8.6 Academic Medical Centers
   
9 Global Companion Diagnostics Market, By Geography
 9.1 North America
  9.1.1 US
  9.1.2 Canada
  9.1.3 Mexico
 9.2 Europe 
  9.2.1 Germany
  9.2.2 France
  9.2.3 Italy
  9.2.4 UK
  9.2.5 Spain
  9.2.6 Rest of Europe
 9.3 Asia Pacific
  9.3.1 Japan
  9.3.2 China
  9.3.3 India
  9.3.4 Australia
  9.3.5 New Zealand
  9.3.6 Rest of Asia Pacific
 9.4 Rest of the World
  9.4.1 Middle East
  9.4.2 Brazil
  9.4.3 Argentina
  9.4.4 South Africa
  9.4.5 Egypt
   
10 Key Developments 
 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
 10.2 Acquisitions & Mergers
 10.3 New Product Launch
 10.4 Expansions
 10.5 Other Key Strategies
   
11 Company Profiling 
 11.1 Roche Diagnostics 
 11.2 Quest Diagnostics Inc.
 11.3 Qiagen N.V. 
 11.4 Labcorp  
 11.5 Genomic Health Inc.
 11.6 Dako (Agilent Technologies)
 11.7 Celera  
 11.8 Biomerieux Sa 
 11.9 Abbott Laboratories 
 11.10 Thermo Fisher Scientific, Inc. 
 11.11 Danaher Corporation
 11.12 GE Healthcare  
 11.13 Biogenex Laboratories 
 11.14 Siemens  
 11.15 AstraZeneca 


List of Tables
1 Global Companion Diagnostics Market Outlook, By Region (2013-2022) ($MN)
2 Global Companion Diagnostics Market Outlook, By Technology (2013-2022) ($MN)
3 Global Companion Diagnostics Market Outlook, By Molecular diagnostics (2013-2022) ($MN)
4 Global Companion Diagnostics Market Outlook, By In Situ Hybridization (ISH) (2013-2022) ($MN)
5 Global Companion Diagnostics Market Outlook, By Polymerase Chain Reaction (PCR) (2013-2022) ($MN)
6 Global Companion Diagnostics Market Outlook, By Next generation sequencing (2013-2022) ($MN)
7 Global Companion Diagnostics Market Outlook, By Other Technologies (2013-2022) ($MN)
8 Global Companion Diagnostics Market Outlook, By Immunohistochemistry (2013-2022) ($MN)
9 Global Companion Diagnostics Market Outlook, By Application (2013-2022) ($MN)
10 Global Companion Diagnostics Market Outlook, By Colorectal Cancer (2013-2022) ($MN)
11 Global Companion Diagnostics Market Outlook, By Gastric Cancer (2013-2022) ($MN)
12 Global Companion Diagnostics Market Outlook, By Lung Cancer (2013-2022) ($MN)
13 Global Companion Diagnostics Market Outlook, By Breast Cancer (2013-2022) ($MN)
14 Global Companion Diagnostics Market Outlook, By Melanoma (2013-2022) ($MN)
15 Global Companion Diagnostics Market Outlook, By Other Applications (2013-2022) ($MN)
16 Global Companion Diagnostics Market Outlook, By Indication (2013-2022) ($MN)
17 Global Companion Diagnostics Market Outlook, By Cardiovascular conditions (2013-2022) ($MN)
18 Global Companion Diagnostics Market Outlook, By Inflammation (2013-2022) ($MN)
19 Global Companion Diagnostics Market Outlook, By Virology (2013-2022) ($MN)
20 Global Companion Diagnostics Market Outlook, By Oncology (2013-2022) ($MN)
21 Global Companion Diagnostics Market Outlook, By Other Indications (2013-2022) ($MN)
22 Global Companion Diagnostics Market Outlook, By End User (2013-2022) ($MN)
23 Global Companion Diagnostics Market Outlook, By Pharmaceutical Companies (2013-2022) ($MN)
24 Global Companion Diagnostics Market Outlook, By Reference Lab (2013-2022) ($MN)
25 Global Companion Diagnostics Market Outlook, By Physicians (2013-2022) ($MN)
26 Global Companion Diagnostics Market Outlook, By Hospitals (2013-2022) ($MN)
27 Global Companion Diagnostics Market Outlook, By Academic Medical Centers (2013-2022) ($MN)
28 North America Companion Diagnostics Market Outlook, By Technology (2013-2022) ($MN)
29 North America Companion Diagnostics Market Outlook, By Molecular diagnostics (2013-2022) ($MN)
30 North America Companion Diagnostics Market Outlook, By In Situ Hybridization (ISH) (2013-2022) ($MN)
31 North America Companion Diagnostics Market Outlook, By Polymerase Chain Reaction (PCR) (2013-2022) ($MN)
32 North America Companion Diagnostics Market Outlook, By Next generation sequencing (2013-2022) ($MN)
33 North America Companion Diagnostics Market Outlook, By Other Technologies (2013-2022) ($MN)
34 North America Companion Diagnostics Market Outlook, By Immunohistochemistry (2013-2022) ($MN)
35 North America Companion Diagnostics Market Outlook, By Application (2013-2022) ($MN)
36 North America Companion Diagnostics Market Outlook, By Colorectal Cancer (2013-2022) ($MN)
37 North America Companion Diagnostics Market Outlook, By Gastric Cancer (2013-2022) ($MN)
38 North America Companion Diagnostics Market Outlook, By Lung Cancer (2013-2022) ($MN)
39 North America Companion Diagnostics Market Outlook, By Breast Cancer (2013-2022) ($MN)
40 North America Companion Diagnostics Market Outlook, By Melanoma (2013-2022) ($MN)
41 North America Companion Diagnostics Market Outlook, By Other Applications (2013-2022) ($MN)
42 North America Companion Diagnostics Market Outlook, By Indication (2013-2022) ($MN)
43 North America Companion Diagnostics Market Outlook, By Cardiovascular conditions (2013-2022) ($MN)
44 North America Companion Diagnostics Market Outlook, By Inflammation (2013-2022) ($MN)
45 North America Companion Diagnostics Market Outlook, By Virology (2013-2022) ($MN)
46 North America Companion Diagnostics Market Outlook, By Oncology (2013-2022) ($MN)
47 North America Companion Diagnostics Market Outlook, By Other Indications (2013-2022) ($MN)
48 North America Companion Diagnostics Market Outlook, By End User (2013-2022) ($MN)
49 North America Companion Diagnostics Market Outlook, By Pharmaceutical Companies (2013-2022) ($MN)
50 North America Companion Diagnostics Market Outlook, By Reference Lab (2013-2022) ($MN)
51 North America Companion Diagnostics Market Outlook, By Physicians (2013-2022) ($MN)
52 North America Companion Diagnostics Market Outlook, By Hospitals (2013-2022) ($MN)
53 North America Companion Diagnostics Market Outlook, By Academic Medical Centers (2013-2022) ($MN)
54 Europe Companion Diagnostics Market Outlook, By Technology (2013-2022) ($MN)
55 Europe Companion Diagnostics Market Outlook, By Molecular diagnostics (2013-2022) ($MN)
56 Europe Companion Diagnostics Market Outlook, By In Situ Hybridization (ISH) (2013-2022) ($MN)
57 Europe Companion Diagnostics Market Outlook, By Polymerase Chain Reaction (PCR) (2013-2022) ($MN)
58 Europe Companion Diagnostics Market Outlook, By Next generation sequencing (2013-2022) ($MN)
59 Europe Companion Diagnostics Market Outlook, By Other Technologies (2013-2022) ($MN)
60 Europe Companion Diagnostics Market Outlook, By Immunohistochemistry (2013-2022) ($MN)
61 Europe Companion Diagnostics Market Outlook, By Application (2013-2022) ($MN)
62 Europe Companion Diagnostics Market Outlook, By Colorectal Cancer (2013-2022) ($MN)
63 Europe Companion Diagnostics Market Outlook, By Gastric Cancer (2013-2022) ($MN)
64 Europe Companion Diagnostics Market Outlook, By Lung Cancer (2013-2022) ($MN)
65 Europe Companion Diagnostics Market Outlook, By Breast Cancer (2013-2022) ($MN)
66 Europe Companion Diagnostics Market Outlook, By Melanoma (2013-2022) ($MN)
67 Europe Companion Diagnostics Market Outlook, By Other Applications (2013-2022) ($MN)
68 Europe Companion Diagnostics Market Outlook, By Indication (2013-2022) ($MN)
69 Europe Companion Diagnostics Market Outlook, By Cardiovascular conditions (2013-2022) ($MN)
70 Europe Companion Diagnostics Market Outlook, By Inflammation (2013-2022) ($MN)
71 Europe Companion Diagnostics Market Outlook, By Virology (2013-2022) ($MN)
72 Europe Companion Diagnostics Market Outlook, By Oncology (2013-2022) ($MN)
73 Europe Companion Diagnostics Market Outlook, By Other Indications (2013-2022) ($MN)
74 Europe Companion Diagnostics Market Outlook, By End User (2013-2022) ($MN)
75 Europe Companion Diagnostics Market Outlook, By Pharmaceutical Companies (2013-2022) ($MN)
76 Europe Companion Diagnostics Market Outlook, By Reference Lab (2013-2022) ($MN)
77 Europe Companion Diagnostics Market Outlook, By Physicians (2013-2022) ($MN)
78 Europe Companion Diagnostics Market Outlook, By Hospitals (2013-2022) ($MN)
79 Europe Companion Diagnostics Market Outlook, By Academic Medical Centers (2013-2022) ($MN)
80 Asia Pacific Companion Diagnostics Market Outlook, By Technology (2013-2022) ($MN)
81 Asia Pacific Companion Diagnostics Market Outlook, By Molecular diagnostics (2013-2022) ($MN)
82 Asia Pacific Companion Diagnostics Market Outlook, By In Situ Hybridization (ISH) (2013-2022) ($MN)
83 Asia Pacific Companion Diagnostics Market Outlook, By Polymerase Chain Reaction (PCR) (2013-2022) ($MN)
84 Asia Pacific Companion Diagnostics Market Outlook, By Next generation sequencing (2013-2022) ($MN)
85 Asia Pacific Companion Diagnostics Market Outlook, By Other Technologies (2013-2022) ($MN)
86 Asia Pacific Companion Diagnostics Market Outlook, By Immunohistochemistry (2013-2022) ($MN)
87 Asia Pacific Companion Diagnostics Market Outlook, By Application (2013-2022) ($MN)
88 Asia Pacific Companion Diagnostics Market Outlook, By Colorectal Cancer (2013-2022) ($MN)
89 Asia Pacific Companion Diagnostics Market Outlook, By Gastric Cancer (2013-2022) ($MN)
90 Asia Pacific Companion Diagnostics Market Outlook, By Lung Cancer (2013-2022) ($MN)
91 Asia Pacific Companion Diagnostics Market Outlook, By Breast Cancer (2013-2022) ($MN)
92 Asia Pacific Companion Diagnostics Market Outlook, By Melanoma (2013-2022) ($MN)
93 Asia Pacific Companion Diagnostics Market Outlook, By Other Applications (2013-2022) ($MN)
94 Asia Pacific Companion Diagnostics Market Outlook, By Indication (2013-2022) ($MN)
95 Asia Pacific Companion Diagnostics Market Outlook, By Cardiovascular conditions (2013-2022) ($MN)
96 Asia Pacific Companion Diagnostics Market Outlook, By Inflammation (2013-2022) ($MN)
97 Asia Pacific Companion Diagnostics Market Outlook, By Virology (2013-2022) ($MN)
98 Asia Pacific Companion Diagnostics Market Outlook, By Oncology (2013-2022) ($MN)
99 Asia Pacific Companion Diagnostics Market Outlook, By Other Indications (2013-2022) ($MN)
100 Asia Pacific Companion Diagnostics Market Outlook, By End User (2013-2022) ($MN)
101 Asia Pacific Companion Diagnostics Market Outlook, By Pharmaceutical Companies (2013-2022) ($MN)
102 Asia Pacific Companion Diagnostics Market Outlook, By Reference Lab (2013-2022) ($MN)
103 Asia Pacific Companion Diagnostics Market Outlook, By Physicians (2013-2022) ($MN)
104 Asia Pacific Companion Diagnostics Market Outlook, By Hospitals (2013-2022) ($MN)
105 Asia Pacific Companion Diagnostics Market Outlook, By Academic Medical Centers (2013-2022) ($MN)
106 Rest of the World Companion Diagnostics Market Outlook, By Technology (2013-2022) ($MN)
107 Rest of the World Companion Diagnostics Market Outlook, By Molecular diagnostics (2013-2022) ($MN)
108 Rest of the World Companion Diagnostics Market Outlook, By In Situ Hybridization (ISH) (2013-2022) ($MN)
109 Rest of the World Companion Diagnostics Market Outlook, By Polymerase Chain Reaction (PCR) (2013-2022) ($MN)
110 Rest of the World Companion Diagnostics Market Outlook, By Next generation sequencing (2013-2022) ($MN)
111 Rest of the World Companion Diagnostics Market Outlook, By Other Technologies (2013-2022) ($MN)
112 Rest of the World Companion Diagnostics Market Outlook, By Immunohistochemistry (2013-2022) ($MN)
113 Rest of the World Companion Diagnostics Market Outlook, By Application (2013-2022) ($MN)
114 Rest of the World Companion Diagnostics Market Outlook, By Colorectal Cancer (2013-2022) ($MN)
115 Rest of the World Companion Diagnostics Market Outlook, By Gastric Cancer (2013-2022) ($MN)
116 Rest of the World Companion Diagnostics Market Outlook, By Lung Cancer (2013-2022) ($MN)
117 Rest of the World Companion Diagnostics Market Outlook, By Breast Cancer (2013-2022) ($MN)
118 Rest of the World Companion Diagnostics Market Outlook, By Melanoma (2013-2022) ($MN)
119 Rest of the World Companion Diagnostics Market Outlook, By Other Applications (2013-2022) ($MN)
120 Rest of the World Companion Diagnostics Market Outlook, By Indication (2013-2022) ($MN)
121 Rest of the World Companion Diagnostics Market Outlook, By Cardiovascular conditions (2013-2022) ($MN)
122 Rest of the World Companion Diagnostics Market Outlook, By Inflammation (2013-2022) ($MN)
123 Rest of the World Companion Diagnostics Market Outlook, By Virology (2013-2022) ($MN)
124 Rest of the World Companion Diagnostics Market Outlook, By Oncology (2013-2022) ($MN)
125 Rest of the World Companion Diagnostics Market Outlook, By Other Indications (2013-2022) ($MN)
126 Rest of the World Companion Diagnostics Market Outlook, By End User (2013-2022) ($MN)
127 Rest of the World Companion Diagnostics Market Outlook, By Pharmaceutical Companies (2013-2022) ($MN)
128 Rest of the World Companion Diagnostics Market Outlook, By Reference Lab (2013-2022) ($MN)
129 Rest of the World Companion Diagnostics Market Outlook, By Physicians (2013-2022) ($MN)
130 Rest of the World Companion Diagnostics Market Outlook, By Hospitals (2013-2022) ($MN)
131 Rest of the World Companion Diagnostics Market Outlook, By Academic Medical Centers (2013-2022) ($MN)

1. What do I do if I have a query on this report?
In case of any queries regarding this report, you can contact the customer service by filing the “Inquiry Before Buy” form available on the right hand side. You may also contact us through email: info@strategymrc.com or phone: +1-301-202-5929
2. Is the sample available for this report? Can I request the sample with my specific requirements?
Yes, the samples are available for all the published reports. You can request them by filling the “Request Sample” option available in this page.
Yes, you can request a sample with your specific requirements. All the customized samples will be provided as per the requirement with the real data masked.
3. Format of the report?
All our reports are available in Digital PDF format. In case if you require them in any other formats, such as PPT, Excel etc you can submit a request through “Inquiry Before Buy” form available on the right hand side. You may also contact us through email: info@strategymrc.com or phone: +1-301-202-5929
4. Services prior to purchase and after purchase?
We offer a free 15% customization with every purchase. This requirement can be fulfilled for both pre and post sale. You may send your customization requirements through email at info@strategymrc.com or call us on +1-301-202-5929.
5. License Type and Delivery?
We have 3 different licensing options available in electronic format.
  • Single User Licence: Allows one person, typically the buyer, to have access to the ordered product. The ordered product cannot be distributed to anyone else.
  • 2-5 User Licence: Allows the ordered product to be shared among a maximum of 5 people within your organisation.
  • Corporate License: Allows the product to be shared among all employees of your organisation regardless of their geographical location.
All our reports are typically be emailed to you as an attachment
6. Purchase procedure and Invoicing?
To order any available report you need to register on our website. The payment can be made either through CCAvenue or PayPal payments gateways which accept all international cards
7. Post sale support?
We extend our support to 6 months post sale. A post sale customization is also provided to cover your unmet needs in the report.

We provide a free 15% customization on every purchase. This requirement can be fulfilled for both pre and post sale. You may send your customization requirements through email at info@strategymrc.com or call us on +1-301-202-5929.

Note: This customization is absolutely free until it falls under the 15% bracket. If your requirement exceeds this a feasibility check will be performed. Post that, a quote will be provided along with the timelines.

Select License Type

Single User License (PDF)

 

2 - 5 User License (PDF)

 

Corporate License (PDF)

 

Have a Question?


Know our Methodology

WHY CHOOSE US ?

Assured Quality

Best in class reports with high standard of research integrity

24X7 Research Support

Continuous support to ensure the best customer experience.

Free Customization

Adding more values to your product of interest.

Safe & Secure Access

Providing a secured environment for all online transactions.

Trusted by 600+ Brands

Serving the most reputed brands across the world.

Testimonials